Details for Patent: 11,679,119
✉ Email this page to a colleague
Which drugs does patent 11,679,119 protect, and when does it expire?
Patent 11,679,119 protects BORTEZOMIB and is included in one NDA.
This patent has one patent family member in one country.
Drugs Protected by US Patent 11,679,119
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Maia Pharms Inc | BORTEZOMIB | bortezomib | SOLUTION;INTRAVENOUS | 215331-001 | Jul 27, 2022 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA | ⤷ Sign Up | ||||
Maia Pharms Inc | BORTEZOMIB | bortezomib | SOLUTION;INTRAVENOUS | 215331-001 | Jul 27, 2022 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA | ⤷ Sign Up | ||||
Maia Pharms Inc | BORTEZOMIB | bortezomib | SOLUTION;INTRAVENOUS | 215331-002 | Jul 27, 2022 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA | ⤷ Sign Up | ||||
Maia Pharms Inc | BORTEZOMIB | bortezomib | SOLUTION;INTRAVENOUS | 215331-002 | Jul 27, 2022 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,679,119
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
World Intellectual Property Organization (WIPO) | 2023049346 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |